Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Dermatology

Understanding Cutaneous Lupus Erythematosus

At a Glance

Cutaneous Lupus Erythematosus (CLE) is an autoimmune condition where the immune system mistakenly attacks the skin, causing rashes and inflammation. Unlike systemic lupus, CLE is usually limited to the skin, has a normal life expectancy, and is most commonly triggered by UV light exposure.

Receiving a diagnosis of Cutaneous Lupus Erythematosus (CLE) often triggers an immediate sense of alarm. It is common to hear the word “lupus” and assume it means a life-threatening systemic disease that affects the heart, lungs, and kidneys. However, it is vital to understand that CLE is a skin-focused condition [1][2]. While it requires careful management and monitoring, many people with CLE live full, active lives without ever developing the systemic version of the disease [3][4].

Three Stabilizing Facts for the Newly Diagnosed

  1. Skin Lupus is Often Skin-Only: CLE is an autoimmune disease where the body’s immune system mistakenly attacks only the skin [5]. While it can be part of Systemic Lupus Erythematosus (SLE), many patients have “skin-limited” disease that does not involve internal organs [1][4].
  2. Normal Life Expectancy: Research shows that patients with CLE experience mortality rates comparable to those of the general population [3].
  3. Lower Progression Risk Than Once Thought: Recent studies suggest that the risk of CLE progressing to systemic lupus (SLE) is lower than older medical literature previously estimated [4].

How CLE Affects the Body

The biological mechanism of CLE is often described as an “interferon-driven” process [6]. Interferons are proteins that normally help your body fight off viruses, but in CLE, they become overactive and signal the immune system to attack healthy skin cells [7].

This attack happens primarily at the “interface” or boundary between the epidermis (the outer layer of skin) and the dermis (the deeper layer) [8]. When immune cells attack this boundary, it causes chronic inflammation that leads to the visible rashes, flaking, or scarring associated with the disease [8].

The Role of Triggers

CLE typically involves a combination of genetic susceptibility and environmental triggers. Ultraviolet (UV) light is the most significant trigger [9]. When UV rays hit the skin, they cause skin cells to release their internal contents, which the immune system misidentifies as a threat [9]. This activates the interferon pathway and draws immune cells like T-cells into the skin, creating or worsening a flare [10][11]. Other common triggers include smoking and certain medications, such as those used for high blood pressure or acid reflux [12][13].

Understanding Your Risks

While the outlook for CLE is generally positive, it is a chronic condition that requires a proactive approach:

  • Subtype Matters: Different forms of CLE, such as Discoid Lupus (DLE) or Subacute Cutaneous Lupus (SCLE), have different risks for systemic progression and skin scarring [1][8]. DLE is the most common form and is often limited to the skin, though it can cause scarring [14].
  • Incidence: CLE is relatively rare, with approximately 4.3 new cases diagnosed per 100,000 people each year [15][12].
  • Long-term Health: While systemic lupus is the primary concern, patients with CLE should also be monitored for other autoimmune conditions and cardiovascular health, as chronic inflammation can sometimes impact the heart or blood vessels over many years [16][17].

Monitoring usually involves regular skin exams and periodic blood or urine tests to ensure that the disease remains limited to the skin [18][19].

Common questions in this guide

Is cutaneous lupus the same as systemic lupus?
No, cutaneous lupus erythematosus (CLE) is primarily limited to the skin. While it can occur alongside systemic lupus (SLE), many people with CLE never develop the systemic version that affects internal organs.
What are the most common triggers for a skin lupus flare?
Ultraviolet (UV) light from the sun is the most significant trigger for skin lupus flares. Other common triggers include smoking and certain medications, such as those prescribed for high blood pressure or acid reflux.
Does skin lupus shorten your life expectancy?
Research shows that people with cutaneous lupus generally experience mortality rates comparable to the general population. It is a chronic condition that can be managed without typically affecting your overall lifespan.
What are the different types of cutaneous lupus?
The main subtypes include Discoid Lupus (DLE), Subacute Cutaneous Lupus (SCLE), and Acute Cutaneous Lupus. DLE is the most common form and can cause skin scarring, but it is typically limited to the skin.
How is cutaneous lupus monitored over time?
Monitoring typically involves regular skin exams by your doctor. You may also need periodic blood and urine tests, such as ANA titers and kidney function tests, to ensure the disease remains limited to the skin.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific subtype of CLE do I have (Discoid, Subacute, or Acute), and how was this confirmed?
  2. 2.What were the results of my initial screening tests for systemic involvement, specifically my ANA titer and kidney function?
  3. 3.Given my subtype and test results, what is my personal estimated risk of developing systemic lupus?
  4. 4.Are any of my current medications (like blood pressure or acid reflux drugs) known to trigger drug-induced skin lupus?
  5. 5.What is our plan for monitoring my health over the next year to catch any changes early?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus.

    Fetter T, Braegelmann C, de Vos L, Wenzel J

    Frontiers in medicine 2022; (9()):915828 doi:10.3389/fmed.2022.915828.

    PMID: 35712102
  2. 2

    Systemic lupus erythematosus is a risk factor for having multiple subtypes of cutaneous lupus erythematosus.

    Lu G, Brown LS, Chong BF

    Lupus 2025; (34(2)):181-186 doi:10.1177/09612033241311335.

    PMID: 39707863
  3. 3

    Epidemiology of Cutaneous Lupus Erythematosus Among Adults Over Four Decades (1976-2018): A Lupus Midwest Network (LUMEN) Study.

    Hocaoğlu M, Davis MDP, Osei-Onomah SA, et al.

    Mayo Clinic proceedings 2022; (97(12)):2282-2290 doi:10.1016/j.mayocp.2022.06.022.

    PMID: 36347648
  4. 4

    Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark.

    Petersen MP, Möller S, Bygum A, et al.

    Lupus 2018; (27(9)):1424-1430 doi:10.1177/0961203318777103.

    PMID: 29788808
  5. 5

    An Overview of the Pathogenesis of Cutaneous Lupus Erythematosus.

    Verdelli A, Barletta E, Mariotti EB, et al.

    Journal of clinical medicine 2025; (14(23)) doi:10.3390/jcm14238285.

    PMID: 41375587
  6. 6

    Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics.

    Hile GA, Werth VP

    Arthritis & rheumatology (Hoboken, N.J.) 2025; (77(1)):1-11 doi:10.1002/art.42983.

    PMID: 39262215
  7. 7

    Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies.

    Wenzel J

    Nature reviews. Rheumatology 2019; (15(9)):519-532 doi:10.1038/s41584-019-0272-0.

    PMID: 31399711
  8. 8

    Current Insights in Cutaneous Lupus Erythematosus Immunopathogenesis.

    Garelli CJ, Refat MA, Nanaware PP, et al.

    Frontiers in immunology 2020; (11()):1353 doi:10.3389/fimmu.2020.01353.

    PMID: 32714331
  9. 9

    Current concepts of photosensitivity in cutaneous lupus erythematosus.

    Klein B, Kunz M

    Frontiers in medicine 2022; (9()):939594 doi:10.3389/fmed.2022.939594.

    PMID: 36091671
  10. 10

    Delineating the Healthy Human Skin UV Response and Early Induction of Interferon Pathway in Cutaneous Lupus Erythematosus.

    Katayama S, Panelius J, Koskenmies S, et al.

    The Journal of investigative dermatology 2019; (139(9)):2058-2061.e4 doi:10.1016/j.jid.2019.02.035.

    PMID: 30974166
  11. 11

    Role of neutrophils in cutaneous lupus erythematosus.

    Yamamoto T

    The Journal of dermatology 2024; (51(2)):180-184 doi:10.1111/1346-8138.17036.

    PMID: 38009863
  12. 12

    Cutaneous lupus erythematosus: clinico-pathologic correlation.

    Filotico R, Mastrandrea V

    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2018; (153(2)):216-229 doi:10.23736/S0392-0488.18.05929-1.

    PMID: 29368845
  13. 13

    Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 IFN in Cutaneous Lupus: An In-Depth Immunoprofile of Subacute and Discoid Lupus.

    Vazquez T, Patel J, Kodali N, et al.

    The Journal of investigative dermatology 2024; (144(6)):1262-1272.e7 doi:10.1016/j.jid.2023.10.039.

    PMID: 38086428
  14. 14

    Persistent red and swollen eyelids.

    Maya Y, Tashimo A, Ota M

    Lancet (London, England) 2018; (392(10157)):1552 doi:10.1016/S0140-6736(18)32327-4.

    PMID: 30496061
  15. 15

    Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment.

    Hejazi EZ, Werth VP

    American journal of clinical dermatology 2016; (17(2)):135-46 doi:10.1007/s40257-016-0173-9.

    PMID: 26872954
  16. 16

    Polyautoimmunity in patients with cutaneous lupus erythematosus: A nationwide sex- and age-matched cohort study from Denmark.

    Graven-Nielsen CS, Vittrup IV, Kragh AJ, et al.

    JAAD international 2023; (13()):126-133 doi:10.1016/j.jdin.2023.07.018.

    PMID: 37808964
  17. 17

    Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study.

    Shams-Eldin AN, Yafasova A, Faurschou M, et al.

    Clinical rheumatology 2022; (41(11)):3525-3536 doi:10.1007/s10067-022-06302-z.

    PMID: 35907102
  18. 18

    Cutaneous lupus erythematosus - from pathogenesis to targeted therapy.

    Klein B, Billi AC, Abernathy-Close L, Kahlenberg JM

    Nature reviews. Rheumatology 2025; (21(12)):703-718 doi:10.1038/s41584-025-01318-6.

    PMID: 41204012
  19. 19

    [Lupus erythematosus].

    Strunz PP, Schmalzing M, Goebeler M, Schmieder A

    Dermatologie (Heidelberg, Germany) 2025; (76(9)):582-600 doi:10.1007/s00105-025-05554-5.

    PMID: 40888883

This page provides educational information about Cutaneous Lupus Erythematosus (CLE). It is not a substitute for professional medical advice, diagnosis, or treatment from your dermatologist or rheumatologist.

Get notified when new evidence is published on Cutaneous lupus erythematosus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.